Antinuclear Antibody Testing Market worth USD 1,476.1 Million USD by 2021

1. MarketsandMarkets Presents Antinuclear Antibody Testing Market worth USD 1,476.1 Million USD by 2021 http://www.marketsandmarkets.com/Market-Reports/antinuclear-antibody-test-market-218189007.html

2. The report "Antinuclear Antibody Test Marketby Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) - Forecast to 2021", report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the ANA testing market, along with revenue estimates & forecasts and market share analysis. Browse 73 market data Tables and 102 Figures spread through 166 Pages and in-depth TOC on "Antinuclear Antibody Test Market” Get The PDF Brochure For This Report: http://www.marketsandmarkets.com/pdfdownload.asp?id=218189007 The global antinuclear antibody test market is expected to reach USD 1,476.1 Million by 2021 from USD 823.5 Million in 2016, at a CAGR of 12.4% from 2016 to 2021. http://www.marketsandmarkets.com/Market-Reports/antinuclear-antibody-test-market-218189007.html

3. Scope of the Report: • This report categorizes the antinuclear antibody test market into the following segments: • Antinuclear Antibody Test Market, by Product • Reagents & Assay Kits • Systems • Software & Services •  Antinuclear Antibody TestMarket, by Disease  • Rheumatoid Arthritis • Systemic Lupus Erythematosus • Sjögren’s Syndrome • Scleroderma • Other Diseases • Antinuclear Antibody TestMarket, by Technique • ELISA • Immunofluorescence Assay • Multiplex Assay • Request Sample of the report: • http://www.marketsandmarkets.com/requestsample.asp?id=218189007 http://www.marketsandmarkets.com/Market-Reports/antinuclear-antibody-test-market-218189007.html

4. Industry Insights: Based on products, the antinuclear antibody test market is segmented into assay kits & reagents, systems, and software & services. The assay kits & reagents segment is expected to account for the largest share of the global ANA testing market in 2016. The growth in this segment can majorly be attributed to the growth in the number of reagent rental agreements and increasing prevalence of autoimmune diseases. The antinuclear antibody test market is segmented into five major disease segments, namely, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, and other diseases. Other diseases include Raynaud’s Syndrome, polymyositis, mixed connective tissue disease, drug-induced lupus, and autoimmune hepatitis. The rheumatoid arthritis segment is expected to account for the largest market share, primarily due to the increasing incidence of rheumatoid arthritis. Based on techniques, the antinuclear antibody test market is segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market due to the expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring. http://www.marketsandmarkets.com/Market-Reports/antinuclear-antibody-test-market-218189007.html

5. Industry Leaders: The major players in this market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.). Geographical Scenario: North America is the largest regional segment in the ANA testing market, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American market is primarily driven by the high incidence of autoimmune diseases, growing population and healthcare spending, and growth in the number of individuals covered under medical insurance in the U.S. http://www.marketsandmarkets.com/Market-Reports/antinuclear-antibody-test-market-218189007.html

6. About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.  http://www.marketsandmarkets.com/Market-Reports/antinuclear-antibody-test-market-218189007.html

7. Contact Us Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441 Email: sales@marketsandmarkets.comMarketsandMarkets Bloghttp://www.marketsandmarkets.comhttp://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets